BlueSky Immunotherapies GmbH Report issue

For profit Phase 1
Founded: Vienna Austria (2016)

Organization Overview

First Clinical Trial
2020
NCT04490512
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

BlueSky Immunotherapies GmbH